Metastatic Hormone Refractory Prostate Cancer
4 clinical trials · Condition
◉ Watch Metastatic Hormone Refractory Prostate Cancer
| Record | Firm | Date |
|---|---|---|
| Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial) (NCT04477512) | Washington University School of Medicine | 2021-02-19 |
| PHA-739358 for Treatment of Hormone Refractory Prostate Cancer (NCT00766324) | Nerviano Medical Sciences | 2007-09-01 |
| Molecular, Genetic, and Genomic Assessments From Patients Treated With RAD001 (NCT00636090) | Duke University | 2007-01-01 |
| Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer (NCT00411528) | Novartis Pharmaceuticals | 2006-09-01 |
Track Metastatic Hormone Refractory Prostate Cancer automatically
Every clearance here is in the API, with alerts when new ones post.